| Code | CSB-RA015007MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BVX20, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a cell surface phosphoprotein exclusively expressed on B lymphocytes from the pre-B cell stage through mature B cells, but absent on plasma cells. This protein plays a crucial role in regulating B-cell activation, proliferation, and differentiation through calcium ion channel activity and signal transduction pathways. MS4A1 is critically important in the pathogenesis of B-cell malignancies and autoimmune disorders, making it a key target for understanding B-cell biology and disease mechanisms.
BVX20 (ofatumumab) is a fully humanizedized anti-CD20 monoclonal antibody that binds to a distinct epitope on the MS4A1 molecule, offering enhanced complement-dependent cytotoxicity compared to earlier generation anti-CD20 therapeutics. This biosimilar antibody serves as a valuable research tool for investigating B-cell depletion mechanisms, studying lymphoproliferative disorders, exploring autoimmune disease pathways, and evaluating novel therapeutic strategies targeting the B-cell compartment in various immunological contexts.
There are currently no reviews for this product.